ESMO Sarcoma and Rare Cancers 2023 | Repurposing abiraterone for the treatment of AR+ salivary gland carcinomas

Alfredo Berruti, MD, University of Brescia, Brescia, Italy, discusses the potential therapeutic efficacy of the prostate cancer drug, abiraterone, in the management of androgen receptor positive (AR+) salivary gland carcinomas. Dr Berruti goes on to explain that the mechanism of action of abiraterone works by selectively inhibiting 17 α hydroxylase leading to a reduction in both androgen and cortisol hypersecretion. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.